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Introduction:
Stroma-derived factors have long been known to influence cancer progression (1) , and the importance of the microenvironment for molecular classification of colorectal cancer (CRC) tumors has been confirmed (2, 3) . These studies highlight the influence of the nonneoplastic component of the tumor on patient prognosis. Expression of PD-L1, the immune checkpoint inhibitor, has been primarily detected on the surface of epithelial neoplastic cells in a number of cancers; however, in CRC, immunohistochemistry (IHC)-based studies of small cohorts have detected high PD-L1 expression in the stromal and immune compartments (4, 5) . Although upregulation of PD-L1 in the tumor microenvironment is a recognized tumor immune-defense mechanism, these findings suggest a different origin for PD-L1 protein expression in CRC.
The mismatch repair system (MMR) helps preserve the fidelity of the genome (6, 7) . CRCs which harbor defects in MMR demonstrate high microsatellite instability (MSI) and account for 12-15% of CRCs. MSI tumors are generally defined by their large number of somatic mutations, compared to microsatellite stable (MSS) tumors. These tumors also exhibit heavy peritumoral/intratumoral lymphocytic infiltration, most likely due to a large number of mutated antigenic epitopes at the cell surface; this has been previously correlated with good prognosis in early stage disease (8) .
A number of adjuvant trials have questioned the value of chemotherapy for defined CRC molecular subtypes in early stage disease, with some studies suggesting potential harm, particularly to the overall good prognosis MSI group (9) . Although preclinical data inferred that MSI tumors would not respond to 5FU-based treatment (10), the first large adjuvant study published using MSI status to stratify patients revealed that patients with MSI tumors did benefit from addition of chemotherapy following surgery (11). However, 11 subsequent studies have shown no benefit from 5FU-based treatment for patients with MSI CRC in the adjuvant setting (9) .
Recent clinical studies in melanoma, renal cell carcinoma, and non-small cell lung cancer have reported significant positive responses to PD-1 checkpoint targeting (12) . In contrast, results in CRC have been disappointing (12 are required.
The extremely promising results in stage IV disease prompted us to evaluate the potential for immune checkpoint-targeting in the adjuvant setting. We performed extensive bioinformatics analyses employing well-characterized independent transcriptional profiling datasets to determine (i) whether PD-L1 gene expression is associated with specific cell lineage compartments within the CRC tumor microenvironment; (ii) ability to stratify patients in early stage CRC using PD-L1 gene expression and determine its association with MSI status/immune infiltration; and (iii) clinical relevance of PD-L1 gene expression to both prognosis and potential for benefit from adjuvant chemotherapy.
Materials and Methods

Independent datasets
Gene expression profiles from independent CRC datasets were downloaded from NCBI 
Transcriptional analysis
Partek Genomics Suite was used for independent dataset analysis. For the purpose of clustering, data matrices were standardized to the median value of probe sets expression.
Standardization of the data allows for comparison of expression levels for different probe sets. Following standardization, 2-dimensional hierarchical clustering was performed (samples x probe sets/genes). Euclidean distance was used to calculate the distance matrix, a multidimensional matrix representing the distance from each data point (probe set-sample pair) to all the other data points. Ward's linkage method was subsequently applied to join samples and genes together, with the minimum variance, to find compact clusters based on the calculated distance matrix.
Statistics
Median and tertile stratification was performed on GSE13294 by calculation of mean expression values from both CD274 probe-sets. These values were then classified as high and low based on 77:78 sample distributions or as high, medium, and low based on 52:51:52 sample distributions. Student t tests and Fishers exact tests were carried out using GraphPad Prism version 5 for Windows, GraphPad Software.
Survival analysis
Survival curves, comparing expression and treatment subgroups were estimated with the Kaplan-Meier method and compared by the log-rank test, using GraphPad Prism version 5
for Windows, GraphPad Software. Cox Proportional Hazards analysis, using Stata version In addition to PD-L1, expression of other immune therapy targets (CTLA4, LAG3, and IDO1)
has also been reported to be upregulated in immune infiltrating cells of MSI tumors compared to MSS tumors(4), although their gene expression levels in individual cell compartments have not been assessed. Using region-specific and cell-specific gene expression profiles, we found CTLA4 (6.3 fold, P < 0.001), LAG3 (4.5 fold, P < 0.001), PD-L1 (4.2 fold, P < 0.001), and IDO1 (9.2 fold, P < 0.001) are all elevated in stroma compared to epithelium in CRC tumor samples (Fig. 1D ). Whereas IDO1 expression was elevated in all stromal compartments compared to epithelial cells, the elevated expression of CTLA4, LAG3, and PDL1 was confined to the leukocyte-specific compartment ( Fig. 1E and F) . We also confirm that expression of interferon-γ (IFNG) is specific to the immune-derived compartment ( Supplementary Fig. S1E ), consistent with previous findings (14) .
Collectively, these analyses provide compelling evidence that PD-L1 in colorectal tumors is predominantly derived from infiltrating immune cells rather than neoplastic epithelial cells.
Association between MSI, immune infiltration, and PD-L1 gene expression
To assess whether the clinical associations between PD-L1 gene expression and MSI 
Identification of a subgroup of patients with high PD-L1 gene expression
Utilizing hierarchical clustering of microarray gene expression profiles from a large stage II/III CRC dataset (GSE39582), and employing Euclidean and Ward metrics, we identified a distinct subgroup of patients with high PD-L1 gene expression relative to the remaining population (Fig. 3A) . This PD-L1 high subgroup accounted for 20% of the overall cohort, which we use as our threshold for all subsequent analyses; further investigation highlighted a strong correlation between elevated PD-L1 gene expression and MSI genotype (Fishers exact two-tailed test P < 0.0001; Fig. 3A and B, Supplementary Fig. S3A ), further validating our earlier findings (Fig. 2) .
Stratification of the data was performed to facilitate an evaluation of the available S3B ), in addition to significant upregulation of IFNγ (two-tailed Student t-test P < 0.001, Supplementary Fig. S3C ).
PD-L1 is a significant positive prognostic marker in early stage disease
To investigate the clinical relevance of PD-L1 gene expression, we used relapse follow-up data associated with the well-characterized GSE39582 dataset. Patients (n = 201) were stratified based on PD-L1 subgroup, stage and treatment. In the untreated stage III population, we found a clear difference in relapse-free survival (RFS) between low and high PD-L1 subgroups, with the PD-L1 low subgroup having a significantly worse outcome (P = 0.0003; HR = 9.09; 95% CI, 2.11-39.10; Fig. 4A and B; Table 2 ). However, in the treated cohort, the correlation between survival and high PD-L1 expression was lost (P = 0.6514; HR = 0.86; 95% CI, 0.45-1.66), suggesting that PD-L1 gene expression also has value for predicting benefit from standard adjuvant chemotherapy (Fig. 4B , Table 2 ).
To address this question, we performed treatment interaction analyses and found that, whereas patients with low expression of the PD-L1 gene significantly benefit from adjuvant chemotherapy (P = 0.0062; HR = 0.49; 95%CI, 0.29-0.83), patients in the PD-L1 high subgroup have poorer overall survival following treatment (P = 0.0208; HR = 4.95; 95%CI, 1.10-22.35; Fig. 4A and B; Table 2 ). An adjusted analysis for the known confounders and covariates of PD-L1 gene expression ( Table 1 ) again confirmed that PD-L1 gene-expression could be considered as an independent biomarker for patient stratification, as although the prognostic and predictive trend remained the same, the adjusted multivariate significance was lost (Table 2 ).
In order to confirm these findings in an independent patient cohort, we interrogated a further early stage CRC dataset (GSE14333). Patients (n = 185) were again stratified into high and low PD-L1 subgroups in similar proportions as identified using our initial dataset. In Dukes' B patients within this cohort, high PD-L1 gene expression was significantly associated with better disease-free survival (DFS) in the untreated population compared to those who received adjuvant treatment (P = 0.0371; HR = 10.18; CI, 1.15-90.14). This trend was also observed in the combined Dukes B/C cohort, but failed to reach significance, most likely due to the small number of patients in this combined cohort compared to the original dataset (Fig. 4C ).
These data indicate that TME-derived PD-L1 transcription levels are both a positive prognostic marker for improved relapse/disease-free survival in early stage disease, but importantly also are a negative predictive marker for chemotherapy in the adjuvant setting. however there is still debate as to the benefit of adjuvant chemotherapy in this group (9) .
Recently, a large meta-analysis concluded that there was no effect of adjuvant treatment for MSI patients, whereas there was a significant benefit in MSS patients (15) . Data presented here show for the first time that high PD-L1 transcription levels, which is significantly associated with the MSI genotype, identify a subgroup of patients with a significantly better prognosis in early stage disease. In addition, we also show that this PD-L1 high subgroup derives no clinical benefit and indeed may be harmed by adjuvant 5-FU-based chemotherapy using an unadjusted analysis.
Although this dataset, and the independent validation set, were not generated from material In conclusion, data presented here, alongside data from the metastatic trial (13) Table 2   Table 2 : Unadjusted and adjusted analyses of relapse-free survival. RFS analysis was performed using Cox proportional hazards method stratified by PD-L1 levels or treatment expression levels. Analysis was performed both before and following adjustment.
